<DOC>
	<DOCNO>NCT00415246</DOCNO>
	<brief_summary>To identify proportion patient remain medically castrate ( testosterone level &lt; 50 ng/dL ) Day 240 follow two administration 4-month sustained-release ( SR ) formulation triptorelin .</brief_summary>
	<brief_title>Study Evaluate Subcutaneous Four Months Sustained-Release Formulation Triptorelin Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Patient must give write ( personally sign date ) inform consent complete studyrelated procedure , mean assessment evaluation would form part normal medical care patient Patient must 18 year old Patient must histologicallyconfirmed diagnosis locally advance metastatic prostate cancer present relapse curative treatment amenable androgen deprivation therapy Patient must estimate survival time great 8 month accord investigator 's assessment Patient risk serious complication case tumour flare ( vertebral metastasis threaten spinal cord compression significant obstructive uropathy ) Patient underwent previous surgical castration Prostate cancer therapy within 2 month baseline visit Patient testosterone level 150 ng/dL screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>